Additionally, these pharmacological interventions ameliorated hepatic steatosis, as well as several biomarkers of liver fibrosis, although the beneficial effects on histology and other clinical outcomes of NASH were not satisfactory [190,191,193], suggesting that more comprehensive and targeted approaches are required to improve the therapeutic efficacy and safety of FGF21 analogues. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.